Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of MEDI3506 in COPD with Chronic Bronchitis
2020-000571-20Phase 2Unknown
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) comparing MEDI3506 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 12 in pre-bronchodilator FEV1. Status: unknown.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on 2020-000571-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000571-20.